| 1 |
Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features[J]. Cancer, 1980, 46(2)：372-379.
|
| 2 |
Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68[J]. Mod Pathol, 2011, 24(3)：390-395.
|
| 3 |
Eggert T, McGlynn KA, Duffy A, et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database[J]. United European Gastroenterol J, 2013, 1(5)：351-357.
|
| 4 |
Ramai D, Ofosu A, Lai JK，et al. Fibrolamellar hepatocellular carcinoma: a population-based observational study[J]. Dig Dis Sci, 2021, 66(1)：308-314.
|
| 5 |
Mayo SC, Mavros MN, Nathan H, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective[J]. J Am Coll Surg, 2014, 218(2)：196-205.
|
| 6 |
Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood[J]. AMA J Dis Child, 1956, 91(2)：168-186.
|
| 7 |
Wege H, Schulze K, von Felden J, et al. Rare variants of primary liver cancer: fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas[J]. Eur J Med Genet, 2021, 64(11)：104313.
|
| 8 |
Depauw L, De Weerdt G, Gys B, et al. Pediatric fibrolamellar hepatocellular carcinoma: case report and review of the literature[J]. Acta Chir Belg, 2021, 121(3)：204-210.
|
| 9 |
Torbenson M. Fibrolamellar carcinoma: 2012 update[J]. Scientifica (Cairo), 2012：743790.
|
| 10 |
Graham RP. Fibrolamellar carcinoma: what is new and why it matters[J]. Surg Pathol Clin, 2018, 11(2)：377-387.
|
| 11 |
O′Neill AF, Church AJ, Perez-Atayde AR, et al. Fibrolamellar carcinoma: an entity all its own[J]. Curr Probl Cancer, 2021, 45(4)：100770.
|
| 12 |
Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event[J]. World J Gastrointest Oncol, 2022, 14(6)：1103-1114.
|
| 13 |
Chakrabarti S, Tella SH, Kommalapati A, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma[J]. J Gastrointest Oncol, 2019, 10(3)：554-561.
|
| 14 |
Aziz H, Brown ZJ, Panid Madani S, et al. Fibrolamellar hepatocellular carcinoma: comprehensive review of diagnosis, imaging, and management[J]. J Am Coll Surg, 2023, 236(2)：399-410.
|
| 15 |
Wege H, Campani C, de Kleine R, et al. Rare primary liver cancers: an EASL position paper[J]. J Hepatol, 2024, S0168-8278(24)02305-5.
|
| 16 |
Sergi CM. Hepatocellular carcinoma, fibrolamellar variant: diagnostic pathologic criteria and molecular pathology update. A primer[J]. Diagnostics (Basel), 2015, 6(1)：3.
|
| 17 |
梁霄，梁岳龙，吕杰敏，等. 腹腔镜ⅶ、ⅷ段肝肿瘤切除术的临床疗效及经验总结[J]. 中华消化外科杂志，2017, 16(8): 860-864.
|
| 18 |
刘荣. 肝脏流域划分及靶域切除手术分级[J/OL]. 中华腔镜外科杂志(电子版), 2023, 16(3)：131-134.
|
| 19 |
姚小晓，盛基尧，张学文. 重视Laennec包膜在解剖性肝切除中的应用[J]. 国际外科学杂志，2022, 49(4): 228-231，F3.
|
| 20 |
陈超波，余德才. 腹腔镜解剖性肝切除的关键点线面[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(6)：321-328.
|
| 21 |
余德才，曹亚娟，张来柱. 腹腔镜解剖性右半肝切除治疗进展期肝细胞肝癌(Laennec入路联合背侧入路)[J/OL]. 中华腔镜外科杂志(电子版), 2021, 14(4)：235-236.
|
| 22 |
Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience[J]. Eur J Cancer, 2013, 49(12)：2698-2704.
|
| 23 |
Gottlieb S, O′Grady C, Gliksberg A, et al. Early experiences with triple immunochemotherapy in adolescents and young adults with high-risk fibrolamellar carcinoma[J]. Oncology, 2021, 99(5)：310-317.
|
| 24 |
Kim AK, Gani F, Layman AJ, et al. Multiple immune-suppressive mechanisms in fibrolamellar carcinoma[J]. Cancer Immunol Res, 2019, 7(5)：805-812.
|
| 25 |
Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma[J]. Oncologist, 2020, 25(12)：e1837-e1845.
|
| 26 |
Abou-Alfa GK, Meyer T, Do RKG, et al. Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma[J]. Liver Cancer, 2024, 14(1)：58-67.
|
| 27 |
Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma[J]. Science, 2014, 343(6174)：1010-1014.
|
| 28 |
Simon EP, Freije CA, Farber BA, et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma[J]. Proc Natl Acad Sci U S A, 2015, 112(44)：E5916-E5925.
|
| 29 |
Neumayer C, Ng D, Requena D, et al. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma[J]. Mol Ther, 2024, 32(1)：140-151.
|
| 30 |
Bauer J, Köhler N, Maringer Y, et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma[J]. Nat Commun, 2022, 13(1)：6401.
|
| 31 |
Hackenbruch C, Bauer J, Heitmann JS, et al. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion[J]. Front Oncol, 2024, 14：1367450.
|
| 32 |
Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition[J]. Hepatology, 2014, 60(1)：362-398.
|